Oflobest-MZ Oral Suspension is a combination antibiotic formulation containing Ofloxacin (50mg), Metronidazole (120mg), and Simethicone (10mg) per dose, designed for the effective treatment of mixed bacterial infections of the gastrointestinal tract. Ofloxacin, a fluoroquinolone antibiotic, exhibits broad-spectrum activity against gram-positive and gram-negative bacteria by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial replication. Metronidazole, a nitroimidazole antimicrobial agent, targets anaerobic bacteria and protozoa by disrupting DNA synthesis, making it effective against anaerobic infections commonly encountered in the gastrointestinal system. Simethicone acts as an antiflatulent agent, reducing bloating and discomfort associated with excessive gas by coalescing gas bubbles, facilitating their elimination. This combination is indicated for the treatment of infections such as bacterial gastroenteritis, amoebic dysentery, and mixed anaerobic and aerobic bacterial infections where gas-related symptoms are present. Oflobest-MZ Oral Suspension should be administered as prescribed by a healthcare professional, with dosage adjusted according to the severity of infection and patient response. Caution is advised in patients with hypersensitivity to fluoroquinolones or nitroimidazoles, and it is contraindicated during pregnancy and lactation unless deemed necessary. Adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and, rarely, neurological symptoms.